Literature DB >> 15627235

Potential public health impact of imperfect HIV type 1 vaccines.

Roy Anderson1, Matthew Hanson.   

Abstract

The potential public health impact of imperfect human immunodeficiency virus (HIV) type 1 vaccines was examined by use of deterministic mathematical models of virus transmission. Imperfect vaccines are defined as those that act to favorably alter the typical clinical course of disease in those immunized who acquire infection. The properties examined include a lengthened incubation period; reduced virus load, which acts to lower infectiousness; reduced susceptibility on exposure to infection; and an increase in risk behaviors by those vaccinated. Analyses suggest that, although imperfect vaccines would struggle to block transmission via cohort vaccination of those entering the sexually active age classes, they could have a substantial public health impact, as measured by reduced prevalence and mortality induced by acquired immunodeficiency syndrome (AIDS), provided the case reproductive number of HIV-1 among vaccinated individuals (R(0v)) was less than that among unvaccinated individuals (R(0)). This requires that any lengthening in the incubation period and, hence, the time period over which an infected vaccine recipient can transmit to susceptible sex partners, as well as any increase in risk behaviors, are more than offset by other effects, such as reduced susceptibility to infection and reduced infectiousness. Numerical studies based on a more complex model, which included representation of age, sex, heterogeneity in sexual activity, variable infectiousness, and different mixing patterns between risk groups, were used to confirm the general insights gained from a simple deterministic model.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15627235     DOI: 10.1086/425267

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  15 in total

1.  Mathematical models for HIV transmission dynamics: tools for social and behavioral science research.

Authors:  Susan Cassels; Samuel J Clark; Martina Morris
Journal:  J Acquir Immune Defic Syndr       Date:  2008-03-01       Impact factor: 3.731

Review 2.  Impact of small reductions in plasma HIV RNA levels on the risk of heterosexual transmission and disease progression.

Authors:  Kayvon Modjarrad; Eric Chamot; Sten H Vermund
Journal:  AIDS       Date:  2008-10-18       Impact factor: 4.177

3.  What can HIV vaccine trials teach us about future HIV vaccine dissemination?

Authors:  Peter A Newman; Naihua Duan; Lisa Kakinami; Kathleen Roberts
Journal:  Vaccine       Date:  2008-03-28       Impact factor: 3.641

4.  Macaques vaccinated with simian immunodeficiency virus SIVmac239Delta nef delay acquisition and control replication after repeated low-dose heterologous SIV challenge.

Authors:  Matthew R Reynolds; Andrea M Weiler; Shari M Piaskowski; Holly L Kolar; Ann J Hessell; Madelyn Weiker; Kim L Weisgrau; Enrique J León; W Eric Rogers; Robert Makowsky; Adrian B McDermott; Rosanne Boyle; Nancy A Wilson; David B Allison; Dennis R Burton; Wayne C Koff; David I Watkins
Journal:  J Virol       Date:  2010-06-30       Impact factor: 5.103

5.  Induction of multifunctional human immunodeficiency virus type 1 (HIV-1)-specific T cells capable of proliferation in healthy subjects by using a prime-boost regimen of DNA- and modified vaccinia virus Ankara-vectored vaccines expressing HIV-1 Gag coupled to CD8+ T-cell epitopes.

Authors:  Nilu Goonetilleke; Stephen Moore; Len Dally; Nicola Winstone; Inese Cebere; Abdul Mahmoud; Susana Pinheiro; Geraldine Gillespie; Denise Brown; Vanessa Loach; Joanna Roberts; Ana Guimaraes-Walker; Peter Hayes; Kelley Loughran; Carole Smith; Jan De Bont; Carl Verlinde; Danii Vooijs; Claudia Schmidt; Mark Boaz; Jill Gilmour; Pat Fast; Lucy Dorrell; Tomas Hanke; Andrew J McMichael
Journal:  J Virol       Date:  2006-05       Impact factor: 5.103

6.  Potential population health outcomes and expenditures of HIV vaccination strategies in the United States.

Authors:  Elisa F Long; Margaret L Brandeau; Douglas K Owens
Journal:  Vaccine       Date:  2009-07-08       Impact factor: 3.641

7.  Variation in HIV-1 set-point viral load: epidemiological analysis and an evolutionary hypothesis.

Authors:  Christophe Fraser; T Déirdre Hollingsworth; Ruth Chapman; Frank de Wolf; William P Hanage
Journal:  Proc Natl Acad Sci U S A       Date:  2007-10-22       Impact factor: 11.205

8.  Predicting the impact of a partially effective HIV vaccine and subsequent risk behavior change on the heterosexual HIV epidemic in low- and middle-income countries: A South African example.

Authors:  Kyeen M Andersson; Douglas K Owens; Eftyhia Vardas; Glenda E Gray; James A McIntyre; A David Paltiel
Journal:  J Acquir Immune Defic Syndr       Date:  2007-09-01       Impact factor: 3.731

9.  HIV population-level adaptation can rapidly diminish the impact of a partially effective vaccine.

Authors:  Joshua T Herbeck; Kathryn Peebles; Paul T Edlefsen; Morgane Rolland; James T Murphy; Geoffrey S Gottlieb; Neil Abernethy; James I Mullins; John E Mittler; Steven M Goodreau
Journal:  Vaccine       Date:  2017-12-11       Impact factor: 3.641

10.  HIV treatment as prevention: principles of good HIV epidemiology modelling for public health decision-making in all modes of prevention and evaluation.

Authors:  Wim Delva; David P Wilson; Laith Abu-Raddad; Marelize Gorgens; David Wilson; Timothy B Hallett; Alex Welte
Journal:  PLoS Med       Date:  2012-07-10       Impact factor: 11.069

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.